Aveo Pharmaceuticals, Inc.

Steve Bottega

Jeno Gyuris

Kristan Meetze

Sylvie Vincent

Ting Chen

William M Winston, Jr

Lyne Breault

Solly Weiler

Steven Tyler

Jin-Kyeung Woo

Fang Wang

Christina Fleet

Michael DePrima

May Han

Lorena Lerner

Kerry Whalen

Qing Liu

Andrea Boudrow

James Gifford

Jinwei Jiang

Bin Feng

Richard Nicoletti

Donna McIntosh

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Anti-ErbB3 antibodies

Anti-ERBB3 antibodies

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

Predicting tumor response to anti-ERBB3 antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-ron antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-RON antibodies

Growing community of inventors

Cambridge, MA, United States of America

Steve Bottega